Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques.

[1]  M. Ittmann,et al.  Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates , 2023, Science Translational Medicine.

[2]  Jean A. Niles,et al.  Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates. , 2023, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Goodey,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection , 2022, Journal of acquired immune deficiency syndromes.

[4]  A. Grattoni,et al.  Comprehensive Analysis of Electrostatic Gating in Nanofluidic Systems. , 2022, ACS applied materials & interfaces.

[5]  Min Xu,et al.  Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs) , 2022, Antimicrobial agents and chemotherapy.

[6]  M. Baum,et al.  CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women , 2022, BMJ Open.

[7]  H. Dvory‐Sobol,et al.  Lenacapavir: a first-in-class HIV-1 capsid inhibitor. , 2022, Current opinion in HIV and AIDS.

[8]  A. Grattoni,et al.  Extending Drug Release from Implants via Transcutaneous Refilling with Solid Therapeutics , 2021, Advanced therapeutics.

[9]  Y. Yazdanpanah,et al.  Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine , 2021, Journal of acquired immune deficiency syndromes.

[10]  Y. Kim.  Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention , 2021, Infection & chemotherapy.

[11]  S. Bares,et al.  A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV , 2021, Current opinion in HIV and AIDS.

[12]  G. Rukundo,et al.  Social Networks and Barriers to ART Adherence Among Young Adults (18–24 years) Living with HIV at Selected Primary Health Facilities of South-Western Uganda: A Qualitative Study , 2021, HIV/AIDS.

[13]  A. Goodey,et al.  Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial , 2021, Nature Medicine.

[14]  S. Sarafianos,et al.  Development of Human Immunodeficiency Virus Type 1 Resistance to 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains , 2021, Antimicrobial agents and chemotherapy.

[15]  T. Buclin,et al.  Long-acting antiretrovirals: a new era for the management and prevention of HIV infection , 2021, The Journal of antimicrobial chemotherapy.

[16]  Meihong Lin,et al.  Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters , 2021, Viruses.

[17]  J. Milic,et al.  The Impact of COVID-19 on UNAIDS 90–90–90 Targets: Calls for New HIV Care Models , 2021, Open forum infectious diseases.

[18]  W. Heneine,et al.  Transmitted Drug Resistance Among HIV-1 Diagnoses in the United States, 2014-2018. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Saijuan Zhang,et al.  Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV , 2021, Journal of acquired immune deficiency syndromes.

[20]  M. Dybul,et al.  Ending AIDS as a public health threat by 2030: Time to reset targets for 2025 , 2021, PLoS medicine.

[21]  N. Ford,et al.  The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals , 2021, PLoS medicine.

[22]  H. Karaosmanoğlu.  How does the covid-19 pandemic affect the target 90-90-90? , 2020, Current HIV research.

[23]  S. Demaria,et al.  Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant , 2020, Pharmaceutics.

[24]  E. B. Butler,et al.  Potentiating anti-tumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1. , 2020, International journal of radiation oncology, biology, physics.

[25]  C. Hendrix,et al.  Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. , 2020, The lancet. HIV.

[26]  Jean A. Niles,et al.  Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates , 2020, bioRxiv.

[27]  A. Pimpinelli,et al.  Finite-size charged species diffusion and pH change in nanochannels. , 2020, ACS applied materials & interfaces.

[28]  C. Flexner,et al.  Long-acting implants to treat and prevent HIV infection. , 2019, Current opinion in HIV and AIDS.

[29]  Ewa Bryndza Tfaily,et al.  A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques , 2019, Antimicrobial Agents and Chemotherapy.

[30]  A. Grattoni,et al.  2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[31]  A. Grattoni,et al.  Remotely controlled nanofluidic implantable platform for tunable drug delivery. , 2019, Lab on a chip.

[32]  A. Ballerini,et al.  Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases , 2019, Biomedical Microdevices.

[33]  W. Heneine,et al.  Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection , 2019, Nature Communications.

[34]  A. Ballerini,et al.  Nanofluidic microsystem for sustained intraocular delivery of therapeutics. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[35]  R. Mumper,et al.  Ultra-long-acting removable drug delivery system for HIV treatment and prevention , 2018, Nature Communications.

[36]  R. L. Hood,et al.  Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre‐exposure prophylaxis , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[37]  S. Sarafianos,et al.  Antiretroviral potency of 4′-ethnyl-2′-fluoro-2′-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes , 2018, The Journal of antimicrobial chemotherapy.

[38]  Marian E. Gindy,et al.  Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention , 2018, Antimicrobial Agents and Chemotherapy.

[39]  Michael J Silverberg,et al.  Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  R. L. Hood,et al.  Unexpected behaviors in molecular transport through size-controlled nanochannels down to the ultra-nanoscale , 2018, Nature Communications.

[41]  Tulio de Oliveira,et al.  HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis , 2017, The Lancet. Infectious diseases.

[42]  S. Iacob,et al.  Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment—Clinical Points of View and Practical Considerations , 2017, Front. Pharmacol..

[43]  M. Wainberg,et al.  M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA , 2017, The Journal of antimicrobial chemotherapy.

[44]  G. Gottlieb,et al.  MK-8591 (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture , 2017, Antimicrobial Agents and Chemotherapy.

[45]  Jerome H. Kim,et al.  Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis , 2015, PLoS medicine.

[46]  Douglas J. Taylor,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[47]  R. Veazey,et al.  Early Divergent Host Responses in SHIVsf162P3 and SIVmac251 Infected Macaques Correlate with Control of Viremia , 2011, PloS one.

[48]  J. Allan,et al.  Relative replication capacity of phenotypic SIV variants during primary infections differs with route of inoculation , 2010, Retrovirology.

[49]  D. Rao,et al.  Stigma and social barriers to medication adherence with urban youth living with HIV , 2007, AIDS care.

[50]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.